These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 14501383)

  • 1. Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.
    Gullbo J; Dhar S; Luthman K; Ehrsson H; Lewensohn R; Nygren P; Larsson R
    Anticancer Drugs; 2003 Sep; 14(8):617-24. PubMed ID: 14501383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.
    Gullbo J; Wallinder C; Tullberg M; Lövborg H; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
    Mol Cancer Ther; 2003 Dec; 2(12):1331-9. PubMed ID: 14707274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the cytotoxic activity of melphalan with L-prolyl-m-L-sarcolysyl-L-p-fluorophenylalanine in human tumour cell lines and primary cultures of tumour cells from patients.
    Larsson R; Dhar S; Ehrsson H; Nygren P; Lewensohn R
    Br J Cancer; 1998 Aug; 78(3):328-35. PubMed ID: 9703278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.
    Gullbo J; Lindhagen E; Bashir-Hassan S; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; De La Torre M; Luthman K; Larsson R
    Invest New Drugs; 2004 Nov; 22(4):411-20. PubMed ID: 15292711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.
    Gullbo J; Tullberg M; Våbenø J; Ehrsson H; Lewensohn R; Nygren P; Larsson R; Luthman K
    Oncol Res; 2003; 14(3):113-32. PubMed ID: 14760861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.
    Gullbo J; Wickström M; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
    J Drug Target; 2003 Jul; 11(6):355-63. PubMed ID: 14668056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxicity and DNA cross-linking induced by peptide conjugated m-L-sarcolysin in human melanoma cells.
    Hansson J; Lewensohn R; Ringborg U
    Anticancer Res; 1991; 11(5):1725-30. PubMed ID: 1768043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.
    Wickström M; Johnsen JI; Ponthan F; Segerström L; Sveinbjörnsson B; Lindskog M; Lövborg H; Viktorsson K; Lewensohn R; Kogner P; Larsson R; Gullbo J
    Mol Cancer Ther; 2007 Sep; 6(9):2409-17. PubMed ID: 17876040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Derivatives of melphalan designed to enhance drug accumulation in cancer cells.
    Kupczyk-Subotkowska L; Tamura K; Pal D; Sakaeda T; Siahaan TJ; Stella VJ; Borchardt RT
    J Drug Target; 1997; 4(6):359-70. PubMed ID: 9239576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan.
    Wickström M; Viktorsson K; Lundholm L; Aesoy R; Nygren H; Sooman L; Fryknäs M; Vogel LK; Lewensohn R; Larsson R; Gullbo J
    Biochem Pharmacol; 2010 May; 79(9):1281-90. PubMed ID: 20067771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective tumor apoptosis by MF13, L-prolyl-L-m-[bis(chloroethyl)amino]-phenylalanyl-L-norvaline ethyl ester, a new sarcolysin containing tripeptide.
    Roboz J; Jiang J; Holland JF; Bekesi JG
    Cancer Res; 1997 Nov; 57(21):4795-802. PubMed ID: 9354441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased toxicity and DNA cross-linking by peptide bound m-L-sarcolysin (Peptichemio) as compared to melphalan and m-L-sarcolysin in human melanoma cell lines.
    Lewensohn R; Ehrsson H; Hansson J; Ringborg U
    Anticancer Res; 1991; 11(1):321-4. PubMed ID: 2018366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High anticancer efficacy of L-proline-m-bis (2-chloroethyl) amino-L-phenylalanyl-L-norvaline ethyl ester hydrochloride (MF13) in vivo.
    Jiang JD; Zhang H; Li JN; Roboz J; Qiao WB; Holland JF; Bekesi G
    Anticancer Res; 2001; 21(3B):1681-9. PubMed ID: 11497247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential DNA cross-linking and cytotoxicity in PHA-stimulated human lymphocytes exposed to melphalan, m-L-sarcolysin and peptichemio.
    Lewensohn R; Hansson J; Ringborg U; Ehrsson H
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):783-8. PubMed ID: 3653195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel transport and delivery mechanism underpins the effectiveness of prolyl-m-sarcolysyl-p-fluorophenylalanine (PSF) in a human melanoma xenograft nude-mouse model.
    Dierickx KM; Morandini R; Nguyen TH; Salès F; Kauffmann JM; Ghanem GE
    Pigment Cell Melanoma Res; 2008 Aug; 21(4):439-50. PubMed ID: 18627526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo activity of melflufen (J1)in lymphoma.
    Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J
    BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of peptide bound m-L-sarcolysin (peptichemio) on melphalan resistant human myeloma cells in vitro.
    Lewensohn R; Fernberg JO; Ehrsson H; Merlini G
    Med Oncol Tumor Pharmacother; 1991; 8(4):265-9. PubMed ID: 1820493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical modification of melphalan as a key to improving treatment of haematological malignancies.
    Gajek A; Poczta A; Łukawska M; Cecuda-Adamczewska V; Tobiasz J; Marczak A
    Sci Rep; 2020 Mar; 10(1):4479. PubMed ID: 32161295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
    Kupczyk-Subotkowska L; Siahaan TJ; Basile AS; Friedman HS; Higgins PE; Song D; Gallo JM
    J Med Chem; 1997 May; 40(11):1726-30. PubMed ID: 9171882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo.
    Strese S; Wickström M; Fuchs PF; Fryknäs M; Gerwins P; Dale T; Larsson R; Gullbo J
    Biochem Pharmacol; 2013 Oct; 86(7):888-95. PubMed ID: 23933387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.